MAC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Macerich Co (MAC) is not a strong buy for a beginner, long-term investor at this time. While the technical indicators show bullish momentum, the company's financial performance is weak, with significant YoY declines in revenue, net income, and EPS. Analysts' ratings are mixed, with some optimism about the company's deleveraging plan but concerns about its over-leveraged balance sheet. Options data indicates low trading sentiment, and there are no recent signals from Intellectia Proprietary Trading Signals. Given the user's preference for long-term investment, it would be prudent to wait for stronger financial performance and clearer positive catalysts before investing.
The technical indicators suggest a bullish trend. The MACD is positive and expanding, moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading above key pivot levels. However, the RSI is at 76.669, which is approaching overbought territory, indicating potential resistance to further upward movement.
KeyBanc's upgrade to Overweight with a $25 price target highlights optimism about the company's 'Path Forward Plan' and potential NOI growth. Analysts expect deleveraging and asset dispositions to improve the company's financial position.
Weak financial performance in Q4 2025, with significant YoY declines in revenue (-4.37%), net income (-91.04%), and EPS (-92.13%). Analysts express concerns about the company's over-leveraged balance sheet and challenges in earnings growth compared to peers. Additionally, hedge funds and insiders show neutral trading sentiment, and there are no recent congress trades to indicate influential interest.
In Q4 2025, Macerich reported a revenue decline of -4.37% YoY to $261.7M, a net income drop of -91.04% YoY to -$18.95M, and an EPS decrease of -92.13% YoY to -$0.07. Gross margin also fell by -10.72% YoY to 22.57%. These results indicate significant financial struggles.
Analysts' ratings are mixed. KeyBanc upgraded the stock to Overweight with a $25 price target, citing progress in the company's deleveraging plan. However, other analysts remain cautious due to the company's over-leveraged balance sheet and challenges in earnings growth. Price targets range from $19 to $25, with a general consensus of Neutral to Buy.
